---
title: "Fate Therapeutics Q4 Earnings Summary & Key Takeaways"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277057214.md"
description: "Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings on February 26, 2026, missing estimated earnings with an EPS of $-0.27, matching the estimate. Revenue decreased by $491,000 compared to the previous year. In the last quarter, the company beat EPS estimates by $0.01, leading to a 2.85% drop in share price the following day. Past performance shows fluctuations in EPS and revenue across previous quarters. For more details, visit their earnings calendar."
datetime: "2026-02-26T14:14:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277057214.md)
  - [en](https://longbridge.com/en/news/277057214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277057214.md)
---

# Fate Therapeutics Q4 Earnings Summary & Key Takeaways

**Fate Therapeutics** (NASDAQ:FATE) released its Q4 earnings on Thursday, February 26, 2026 at 09:00 AM.

Here's what's important from the earnings announcement.

### Earnings

Fate Therapeutics missed estimated earnings by 0.0%, reporting an EPS of $-0.27 versus an estimate of $-0.27.

Revenue was down $491 thousand from the same period last year.

### Analysis of Past Earnings

The company beat on EPS by $0.01 in the last quarter, resulting in a 2.85% drop share price change the following day.

Here's a look at Fate Therapeutics's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

\-0.28

\-0.35

\-0.46

\-0.43

**EPS Actual**

\-0.27

\-0.29

\-0.32

\-0.44

**Revenue Estimate**

1.35M

947K

1.20M

1.57M

**Revenue Actual**

1.74M

1.91M

1.63M

1.86M

To track all earnings releases for Fate Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference](https://longbridge.com/en/news/282940584.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham](https://longbridge.com/en/news/282904330.md)
- [Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences](https://longbridge.com/en/news/282206169.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)